Efficacy and safety of gemifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease: open prospective multicentre study
https://doi.org/10.18093/0869-0189-2008-0-6-39-47
Abstract
Objective: to study the clinical and antibacterial efficacy and safety of gemifloxacin in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AE COPD) hospitalized into pulmonology departments. Study design: open non-comparative prospective study. Settings: 25 different pulmonology centres in Russia. A total of 222 patients with AE COPD (156 males and 66 females, mean age 56,4 ± 11,9 years) were included in the study. The majority of patients (70.3 %) were classified as I type Anthonisen of AE COPD. All patients received oral gemifloxacin (Factive® , Veropharm, Russia) 320 mg once daily for 7 days. Clinical and bacteriological outcomes and treatment safety were assessed at the end of therapy (7–8 days of study) and at follow up (14–16 days of study). At the end of therapy (7–8 days) statistically significant improvements were noted in all symptoms of AE COPD (improvement of cough, dyspnea, sputum volume and purulence). No clinical improvement was seen in 5.6 % of patients, so the clinical success rate of gemifloxacin therapy was 94.4 %. Sputum cultures were performed in 73.0 % of patients and in 60.4 % of them respiratory pathogens were isolated. The leading pathogens were Streptococus pneumoniae (37.7 %) and Haemophilus influenzae (27.8 %). Eradication and presumed eradication of all pathogens were 69.4 % and 26.9 %, respectively. The bacteriological success rate of gemifloxacin therapy was 96.3 %. A total of 15 patients reported adverse events (AEs), most frequent AEs was diarrhea (4.7 %). All AEs were no severe and transitory, and did not require the withdrawal of antibiotic therapy. Oral gemifloxacin had high clinical and bacteriological efficacy in hospitalized patients with AE COPD. The treatment with gemifloxacin was generally well tolerated and was convenient to patients.
About the Authors
S. N. Avdeev
ФГУ НИИ пульмонологии ФМБА России
Russian Federation
Russian Federation
G. E. Baimakanova
ФГУ НИИ пульмонологии ФМБА России
Russian Federation
Russian Federation
E. N. Gaidar
Отделение пульмонологии клинической больницы г. Ростова
Russian Federation
Russian Federation
G. L. Ignatova
Кафедра терапии, фтизиопульмонологии и профпатологии УГМАДО
Russian Federation
Russian Federation
I. V. Leshchenko
Уральская государственная медицинская академия; Медицинское объединение "Новая больница"
Russian Federation
Russian Federation
A. G. Chuchalin
ФГУ НИИ пульмонологии ФМБА России
Russian Federation
Russian Federation
References
1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Publication Number 2701, April 2001: 1–100. Available on: www.goldcopd.com
2. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur. Respir. J. 2003; 21 (suppl. 41): 46s–53s.
3. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.
4. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzi# cha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.
5. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest. Dis. 1997; 52: 43–47.
6. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108 (suppl. 3): 43s–52s.
7. Ewig S., Rodriguez#Roisin R., Torres A. Indications for and choice of antibiotics in COPD. In: Similowski T., Whitelaw W.A., Derenne J. P., eds. Clinical management of chronic obstructive pulmonary disease. New York: Marcel Dekker Inc; 2002. 427–449.
8. Fagon J.#Y., Chastre J., Trouillet J.#L. et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am. Rev. Respir. Dis. 1990; 142: 1004–1008.
9. Soler N., Torres A., Ewig S. et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 1998; 157: 1498–1505.
10. Eller J., Ede A., Schaberg T., Niederman M.S. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548.
11. Nouira S., Marghli S., Belghith M. et al. Once daily oral ofloxacin in in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trail. Lancet 2001; 358: 2020–2025.
12. Blasi F., Tarsia P., Aliberti S. et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm. Pharmacol. Therap. 2006; 19: 11–19.
13. O'Donnell J.A., Gelone S.P. The newer fluoroquinolones. Infect. Dis. Clin. N. Am. 2004; 18: 691–716.
14. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 1994; 6: 592–599.
15. Yoo B.K., Triller D.M., Yong C.#S., Lodise T.P. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. Ann. Pharmacother. 2004; 38: 1226–1235.
16. Blondeau J.M., Tillotson G. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections. Internat. J. Antimicrob. Agents 2008; 31: 299–306.
17. Hoban D.J., Bouchillon S.K., Johnson J.L. et al. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn. Microb. Infect. Dis. 2001; 40: 51–57.
18. File T.M., Schlemmer B., Garau J. et al. Efficacy and safety of gemifloxacin in the treatment of community acquired pneumonia: a randomized, double blind comparison with trovafloxacin. J. Antimicrob. Chemother. 2001; 48: 67–74.
19. Lode H., File T.M., Mandell L. et al. Oral gemifloxacin versus sequental therapy with intravenosus ceftriaxone / oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community acquired pneumoniae: a randomized, open label, multicenter study of clinical efficacy and tolerability. Clin. Therapeut 2002; 24: 1915–1936.
20. Leophonte P., File T.M., Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin / clavulanic acid thrice daily for 10 days for the treatment of community acquired pneumonia of suspected pneumococcal origin. Respir Med 2004; 98: 708–720.
21. Anthonisen N.R., Manfreda J., Warren C.P.W. et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
22. Beam T.R. Jr., Gilbert D.N., Lunin C.M., European Working Party. European guidelines for the clinical evaluation of antiinfective drug products. Munich: European Society for Clinical Microbiology and Infectious Diseases; 1993.
23. Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin. Proc. 1975; 50: 339–344.
24. Cabello H., Torres A., Celis R. et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur. Respir. J. 1997; 10: 1137–1144.
25. Miravitlles M., Espinosa C., Fernandez#Laso E. et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40–46.
26. Siempos I.I., Dimopoulos G., Korbila I.P. et al. Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a metaanalysis. Eur. Respir. J. 2007; 29: 1127–1137.
27. Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N., and the Alexander Project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003; 52: 229–246.
28. Rittenhouse S., McCloskey L., Broskey J. et al. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. J. Antimicrob. Chemother. 2000; 45 (suppl. S1): 23–27.
29. McCloskey L., Moore T., Niconovich N. et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J. Antimicrob Chemother 2000; 45 (suppl. S1): 13–21.
30. Biedenbach D.J., Jones R.N. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolonesprevalence results from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 2003; 46: 55–61.
31. Zhanel G.G., Palatnick L., Nichol K.A. et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolatesresults of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 2003; 47: 1867–1874.
32. Karlowsky J.A., Draghi D.C., Thornsberry C. et al. Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US. Int. J. Antimicrob. Agents 2002; 20: 76–85.
33. Davidson R., Cavalcanti R., Brunton J.L. et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 2002; 346: 520–521.
34. Urban C., Rahman N., Zhao X.L. et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J. Infect. Dis. 2001; 184: 794–798.
35. Nazir J., Urban C., Mariano N. et al. Levofloxacin resistant Haemophilus influenzae in a long-term care facility. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, September 27–30, 2002. San Diego; 2002. 96. C2–647.
36. Anderson K.B., Tan J.S., File Jr. T.M. et al. Emergence of levofloxacin resistant pneumococci in immunocompromised adults after therapy for community acquired pneumonia. Clin. Infect. Dis. 2003; 37: 376–381.
37. Zhao X., Drlica K. Restricting the selection of antibiotic-resistant mutantsa general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 2001; 33 (suppl. 3): S147–S156.
38. Sethi S., Fogarty C., Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med. 2004; 98: 697–707.
39. Blondeau J. A review of clinical trials with fluoroquinolones with an emphasis on new agents. Exp. Opin. Invest. Drugs 2000; 9: 383–413.
40. Koeth L.M., Jacobs M.R., Bajaksouzian S. et al. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999–2000. Int. J. Antimicrob. Agents 2002; 19: 33–37.
41. Jones R.N., Biedenbach D.J. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community acquired respiratory tract infectionsNorth American results from the SENTRY Antimicrobial Surveillance Program (19992001). Diagn. Microbiol. Infect. Dis. 2003; 45: 273–278.
42. Wilson R., Langan C., Ball P. et al., Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone / oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir. Med. 2003; 97: 242–249.
43. Wilson R., Schentag J.J., Ball P., 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical out comes. Clin. Ther. 2002; 24: 639–652.
44. Ball P., Wilson R., Mandell L.A. et al. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J. Chemother. 2001; 13: 288–298.
45. File Jr. T.M., Sclemmer B., Garau J. et al. Gemifloxacin versus amoxicillin / in the treatment of acute exacerbations of chronic bronchitis. J. Chemother. 2000; 12: 314–325.
46. Niederman M.S., McCombs J.S., Unger A.N. et al. Treatment costs of acute exacerbations of chronic bronchitis. Clin. Ther. 1999; 21: 576–591.
47. Cupo M., Pypstra R., Young C. Safety of gemifloxacin in adult patients with respiratory and urinary tract infections. Seventh Conference of the Federation of Infection Societies, Manchester, U.K., 29 November 1 December 2000. Abstr. P28.
Review
For citations:
Avdeev S.N., Baimakanova G.E., Gaidar E.N., Ignatova G.L., Leshchenko I.V., Chuchalin A.G. Efficacy and safety of gemifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease: open prospective multicentre study. PULMONOLOGIYA. 2008;(6):39-47. (In Russ.) https://doi.org/10.18093/0869-0189-2008-0-6-39-47
Views:
394
Email this article 